GSK Acquires Nuvalent for $10.6 Billion to Accelerate Lung Cancer Drug Pipeline
GSK’s $10.6 billion all-cash deal for Nuvalent marks its largest acquisition in over a decade, strengthening its oncology portfolio with two late-stage lung cancer therapies.

